search
Back to results

Effectiveness of Remote Ischemic Preconditioning for Prevention of Contrast Induced Acute Kidney Injury in Patients Undergoing Coronary Angiograms. (RIP-CI-AKI)

Primary Purpose

Contrast-induced Acute Kidney Injury (CI-AKI) Following Coronary Angiogram (CI-AKI), Contrast-induced Nephropathy Following Coronary Angiogram (CIN)

Status
Recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Remote Ischemic Preconditioning
Sponsored by
The University of Texas Medical Branch, Galveston
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Contrast-induced Acute Kidney Injury (CI-AKI) Following Coronary Angiogram (CI-AKI) focused on measuring Contrast-induced acute kidney injury (CI-AKI), Coronary angiogram, Contrast-induced nephropathy (CIN)

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • (1) Patients undergoing an interventional or diagnostic radiological procedure in which they receive intravascular contrast, including patients undergoing coronary angiogram +/- percutaneous coronary intervention (PCI) for all clinical indications except those indicated for primary PCI due to STEMI
  • (2) patients presenting with a renal clearance in the range of less than 60 ml/min/1.73 m2 but not declared ESRD
  • (3) Patients who are not yet recruited for other pharmacological or medical device clinical trials.

Exclusion Criteria:

  • (1) Age <18 years
  • (2) Patient on hemodialysis or peritoneal dialysis
  • (3) Simultaneous participation in another interventional study
  • (4) Percutaneous coiling/embolization procedures of the kidney
  • (5) Impossibility to perform RIPC, caused by pathology in both arms (e.g. dystrophy, recent trauma, chronic wounds)
  • (6) No written informed consent
  • (7) Urgent angiography in STEMI
  • (8) Cardiogenic shock requiring catecholamine infusion
  • (9) Systolic blood pressure <80 mmHg
  • (10) Intra-aortic balloon counter-pulsation
  • (11) Contrast medium injection within the previous 30 days
  • (12) Expected impossibility to obtain follow-up data at 6-week follow-up
  • (13) Patients with Raynaud's disease

Sites / Locations

  • University of Texas- Medical Branch (UTMB)Recruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

No Intervention

Arm Label

Remote Ischemic Preconditioning Protocol

Sham Preconditioning Protocol

Arm Description

Outcomes

Primary Outcome Measures

Serum Creatinine
The primary outcome would be the incidence of CI-AKI, which is defined as an increment of serum creatinine ≥ 0.5 mg/dL or a relative increase of ≥ 25% over the baseline value within a period of 48-72 hours after contrast medium administration.

Secondary Outcome Measures

Occurrence of re-hospitalization
The need for a session of hemodialysis
Mortality within 6 weeks of contrast administration
Major adverse events at 6 weeks, which would comprise death from all causes, including cardiovascular death, non-fatal infarction, hemofiltration or hemodialysis, and congestive heart failure leading to hospital admission.

Full Information

First Posted
November 26, 2021
Last Updated
March 31, 2023
Sponsor
The University of Texas Medical Branch, Galveston
search

1. Study Identification

Unique Protocol Identification Number
NCT05147831
Brief Title
Effectiveness of Remote Ischemic Preconditioning for Prevention of Contrast Induced Acute Kidney Injury in Patients Undergoing Coronary Angiograms.
Acronym
RIP-CI-AKI
Official Title
Effectiveness of Remote Ischemic Preconditioning for Prevention of Contrast Induced Acute Kidney Injury in Patients Undergoing Coronary Angiograms.
Study Type
Interventional

2. Study Status

Record Verification Date
March 2023
Overall Recruitment Status
Recruiting
Study Start Date
November 30, 2021 (Actual)
Primary Completion Date
July 31, 2024 (Anticipated)
Study Completion Date
November 30, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
The University of Texas Medical Branch, Galveston

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The use of imaging is increasing in clinical practice, either for diagnosis or intervention. In these imaging processes, contrast medium (CM) is widely used. However, CM administration can induce contrast-induced nephropathy (CI-AKI). CI-AKI is the third most common cause of renal insufficiency, and its incidence varies from 2% to 50% depending on patient risk factors; in addition, studies have shown that CI-AKI occurs in 2% to 25% of patients undergoing coronary intervention. CI-AKI is associated with significant mortality and morbidity in patients undergoing coronary angiography or other diagnostic contrast studies. We assessed the latest promising evidence on the ability of remote ischemic preconditioning (RIPC) to reduce the incidence of CI-AKI in patients undergoing Coronary Angiogram (CA) or diagnostic contrast studies such as CT angiogram, while at the same time being a non-invasive, low cost, easy, and safe method with absence of adverse effects. However, more randomized controlled trials are needed to confirm these preliminary results. The aim of this study is to minimize the incidence of CI-AKI at the University of Texas Medical Branch (UTMB). If found to be an effective method, RIPC would help minimize the incidence of CI-AKI in all institutions across the globe, who would adopt this intervention. The primary objective: i) reduce the rise in creatinine to < 0.5 mg/dL post-CA in moderate to high risk patients and ii) reduce the incidence of renal replacement therapy post-CA in moderate to high risk patients; iii) we also aim to establish that RIPC is safe and effective. We hypothesize that the use of RIPC, when added to standard medical therapy (pre-and post-CA hydration), will mitigate the effects of contrast on the renal vasculature and lessen the incidence of CI-AKI in moderate to high risk patients at the University of Texas Medical Branch. The use of iodinated contrast to visually enhance target vasculature is a widely used diagnostic technique that is performed daily at UTMB, and around the world, for the diagnosis and management of a variety of conditions. A common complication of this procedure is acute kidney injury (AKI), generally referred to as contrast-induced nephropathy (CI-AKI). This complication can range from an isolated rise in serum creatinine to severe renal dysfunction necessitating renal replacement therapy. The incidence of CI-AKI has been reported as approximately 2-50%, depending upon the definition and sensitivity of assay employed to assess GFR in the hospital setting. In addition, CI-AKI is associated with significant mortality and morbidity. If proven to be beneficial, RIPC will bring about a reduction in incidence of CI-AKI, and thus help to reduce hospitalization and mortality from renal etiology following a given contrast procedure.
Detailed Description
The use of imaging is increasing in clinical practice, either for diagnosis or intervention. In these imaging processes, contrast medium (CM) is widely used. However, CM administration can induce contrast-induced nephropathy (CI-AKI). CI-AKI is the third most common cause of renal insufficiency, and its incidence varies from 2% to 50% depending on patient risk factors; in addition, studies have shown that CI-AKI occurs in 2% to 25% of patients undergoing coronary intervention. CI-AKI is associated with significant mortality and morbidity in patients undergoing coronary angiography or other diagnostic contrast studies. We assessed the latest promising evidence on the ability of remote ischemic preconditioning (RIPC) to reduce the incidence of CI-AKI in patients undergoing Coronary Angiogram (CA) or diagnostic contrast studies such as CT angiogram, while at the same time being a non-invasive, low cost, easy, and safe method with absence of adverse effects. However, more randomized controlled trials are needed to confirm these preliminary results. The aim of this study is to minimize the incidence of CI-AKI at the University of Texas Medical Branch (UTMB). If found to be an effective method, RIPC would help minimize the incidence of CI-AKI in all institutions across the globe, who would adopt this intervention. The primary objective: i) reduce the rise in creatinine to < 0.5 mg/dL post-CA in moderate to high risk patients and ii) reduce the incidence of renal replacement therapy post-CA in moderate to high risk patients; iii) we also aim to establish that RIPC is safe and effective. We hypothesize that the use of RIPC, when added to standard medical therapy (pre-and post-CA hydration), will mitigate the effects of contrast on the renal vasculature and lessen the incidence of CI-AKI in moderate to high risk patients at the University of Texas Medical Branch. The use of iodinated contrast to visually enhance target vasculature is a widely used diagnostic technique that is performed daily at UTMB, and around the world, for the diagnosis and management of a variety of conditions. A common complication of this procedure is acute kidney injury (AKI), generally referred to as contrast-induced nephropathy (CI-AKI). This complication can range from an isolated rise in serum creatinine to severe renal dysfunction necessitating renal replacement therapy. The incidence of CI-AKI has been reported as approximately 2-50%, depending upon the definition and sensitivity of assay employed to assess GFR in the hospital setting. In addition, CI-AKI is associated with significant mortality and morbidity. If proven to be beneficial, RIPC will bring about a reduction in incidence of CI-AKI, and thus help to reduce hospitalization and mortality from renal etiology following a given contrast procedure. Risk factors for CI-AKI include age > 75, hypotension, CHF, anemia, diabetes, patients with a baseline serum creatinine greater than 1.5 mg /dL and the volume of contrast media used. The presence of underlying renal dysfunction appears to provide particular susceptibility. Although most studies exclude patients with severe renal dysfunction, Rihal et al. report that in patients with a creatinine >3.0 (and GFR < 30) the incidence of CI-AKI was 31%. Unfortunately, robust strategies to prevent CI-AKI are minimal. Research has examined the use of sodium bicarbonate, adding N-acetylcysteine or holding RAAS (Renin-angiotensin-aldosterone system) blockers but found all these three strategies ineffective. At this time the only validated strategy to prevent CI-AKI is the use of fluid administration to ensure adequate renal perfusion. Pre- and post-procedure intravenous fluid administration is currently considered standard of care. In one study involving 408 patients with intact renal function receiving isotonic saline (NS) (1cc/kg/h before percutaneous angiography and 24 hours after) the incidence of CI-AKI within the following 3 days was 21% in the group without NS and 11% in the NS+ group (p=0.016). Further, CI-AKI was associated with increased risk of death (15.2% vs 2.8%; p<0.0001) and need for renal replacement therapy (13.4% vs 0%; p<0.0001). In another trial involving 216 patients, pre- and post-procedure hydration reduced the incidence of CI-AKI in the hydrated group versus the non-hydrated control group 20.4% versus 35.2%, p< 0.05). These results were confirmed in the POSEIDON trial which also showed that a LVEDP (left ventricular end-diastolic pressure) guided hydration strategy for the prevention of CI-AKI results in an even greater relative and absolute risk reduction in contrast nephropathy in comparison to the standard hydration strategy. The pathophysiology of CI-AKI is thought to involve renal artery vasoconstriction and the development of reactive oxygen species which leads to direct renal oxidative stress and ischemic injury. Kidney Disease Improving Global Outcome (KDIGO) defines CI-AKI as an increase in serum creatinine level ≥0.5 mg/dl or >25% compared with the baseline value within a period of 48-72 hours after contrast media (CM) administration. The definition of Remote Ischemic Preconditioning is not as simple. According to a pathophysiologic concept, repeated short duration ischemia in an organ induces a ''resistance'' to a later prolonged ischemia. That is, a brief period of ischemia induces endogenous protective mechanisms that increase tissue tolerance to subsequent lethal ischemia. This is a physiological adaptive mechanism of protection of tissues faced to hypoperfusion, which has therapeutic potential when ischemia-reperfusion is induced in a targeted way. In 1982, this mechanism called ischemic preconditioning (IPC) was highlighted for the first time on canine models in myocardial infarction. In experiments, cycles of alternating ischemia and reperfusion were applied to dogs by using a balloon to occlude a coronary artery. This allowed the prevention of necrotic myocardial territories. These results have opened prospects on a possible use of this method of preconditioning for myocardial protection as well as preconditioning for renal protection in humans. Our remote ischemic preconditioning protocol would comprise four (4) cycles of 5 min of ischemia followed by 5 min of reperfusion for the experimental group. The BP cuff would be placed around the upper non-dominant arm (e.g upper left arm in a right-handed patient) and inflated to a pressure set at 50 mmHg higher than baseline systolic BP to induce transient ischemia followed by subsequent deflation to ensure 5 minutes of reperfusion in the RIPC group. The absence of distal pulse would be confirmed with Doppler evaluation or palpation of the radial and ulnar artery. In the control group, sham preconditioning would be performed by inflating an upper-arm blood pressure cuff to diastolic pressure levels and then deflating the cuff to 10 mm Hg below diastolic pressure for 5 minutes to maintain nonischemic upper-arm compression for blinding purposes with regard to the patients; this will be followed by complete deflation of cuff for 5 minutes. Again a total of four cycles would be ensured. In individuals presenting with BMI > 30 kg/m2 , a dedicated blood pressure cuff for obese patients will be used. Time from RIPC to the procedure (either CA or diagnostic contrast study) will be within <120 min in all studies. The patients will be randomly assigned in a 1:1 ratio to either the control group or RIPC group. Randomization will be performed by data analysis software, which would determine whether the patient would fall under the RIPC arm vs Sham-procedure arm. All patients will receive standard care for patients with impaired renal function undergoing CA: Recommended hydration will consist of saline 0.9% solution infusion at a rate of 1 mL/Kg/h for 12 hours prior to contrast medium injection and up to 12 hours thereafter, unless there is evidence of fluid overload thus contraindicating further fluid administration. Metformin, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, diuretics, and non-steroidal anti-inflammatory drugs will be discontinued at least 24 hours before the angiography. Blood samples for basic metabolic panel (BMP) would be drawn prior to coronary intervention/diagnostic contrast study and repeated 48-72 hrs following contrast medium administration. A final BMP would be checked at 6 weeks after contrast procedure. Following IRB approval, studies will begin with a target of including 300 patients in the study, with a tentative timeline of three (3) years. We will obtain BMPs on the day of the procedure (to document baseline creatinine), and then repeat 48-72 hrs after CA/diagnostic contrast studies. No additional visits would be required apart from a visit to the phlebotomist for getting the BMP checked within 48-72 hrs and another visit for repeat BMP check at 6 weeks. Almost all of our patients who undergo CA will have a follow-up appointment with their PCP in the next 3-7 days, but no extra visits are required for the study purpose. No extra costs on the part of the patient would be necessary. Our intervention group- remote ischemic preconditioning group- would be subject to four (4) cycles of 5 min of ischemia followed by 5 min of reperfusion for the experimental group. The BP cuff would be placed around the upper non-dominant arm (e.g upper left arm in a right-handed patient) and inflated to a pressure set at 50 mmHg higher than baseline systolic BP to induce transient ischemia followed by subsequent deflation to ensure 5 minutes of reperfusion in the RIPC group. The absence of distal pulse would be confirmed with Doppler evaluation or palpation of the radial and ulnar artery. In the control group, sham preconditioning would be performed by inflating an upper-arm blood pressure cuff to diastolic pressure levels and then deflating the cuff to 10 mm Hg below diastolic pressure for 5 minutes to maintain nonischemic upper-arm compression for blinding purposes with regard to the patients; this will be followed by complete deflation of cuff for 5 minutes. Again a total of four cycles would be ensured. In individuals presenting with BMI > 30 kg/m2 , a dedicated blood pressure cuff for obese patients will be used. Time from RIPC to the procedure (either CA or diagnostic contrast study) will be within <120 min in all studies. In addition to our above mentioned intervention (RIPC), all patients will receive standard of care for patients with impaired renal function undergoing CA as mentioned below (No.1 and No.2) :- No.1: Recommended hydration will consist of saline 0.9% solution infusion at a rate of 1 mL/Kg/h for 12 hours prior to contrast medium injection and up to 12 hours thereafter, unless there is evidence of fluid overload thus contraindicating further fluid administration. No.2: Metformin, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, diuretics, and non-steroidal anti-inflammatory drugs will be discontinued at least 24hours before the angiography.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Contrast-induced Acute Kidney Injury (CI-AKI) Following Coronary Angiogram (CI-AKI), Contrast-induced Nephropathy Following Coronary Angiogram (CIN)
Keywords
Contrast-induced acute kidney injury (CI-AKI), Coronary angiogram, Contrast-induced nephropathy (CIN)

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderOutcomes Assessor
Allocation
Randomized
Enrollment
300 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Remote Ischemic Preconditioning Protocol
Arm Type
Experimental
Arm Title
Sham Preconditioning Protocol
Arm Type
No Intervention
Intervention Type
Other
Intervention Name(s)
Remote Ischemic Preconditioning
Intervention Description
Place blood pressure cuff around upper, non-dominant arm (e.g. upper left arm in a right-handed patient). Inflate blood pressure cuff to a pressure set at 50 mmHg higher than baseline systolic BP to induce ischemia of arm for 5 minutes. Completely deflate blood pressure cuff to allow for 5 minutes of reperfusion. Subjects would undergo 4 cycles of ischemia and reperfusion,
Primary Outcome Measure Information:
Title
Serum Creatinine
Description
The primary outcome would be the incidence of CI-AKI, which is defined as an increment of serum creatinine ≥ 0.5 mg/dL or a relative increase of ≥ 25% over the baseline value within a period of 48-72 hours after contrast medium administration.
Time Frame
Patient's serum creatinine would be measured 48-72 hours after coronary angiogram, and re-measured 6 weeks after coronary angiogram.
Secondary Outcome Measure Information:
Title
Occurrence of re-hospitalization
Time Frame
Within 6 weeks of coronary angiogram
Title
The need for a session of hemodialysis
Time Frame
Within 6 weeks of coronary angiogram
Title
Mortality within 6 weeks of contrast administration
Time Frame
Within 6 weeks of coronary angiogram
Title
Major adverse events at 6 weeks, which would comprise death from all causes, including cardiovascular death, non-fatal infarction, hemofiltration or hemodialysis, and congestive heart failure leading to hospital admission.
Time Frame
Within 6 weeks of coronary angiogram

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: (1) Patients undergoing an interventional or diagnostic radiological procedure in which they receive intravascular contrast, including patients undergoing coronary angiogram +/- percutaneous coronary intervention (PCI) for all clinical indications except those indicated for primary PCI due to STEMI (2) patients presenting with a renal clearance in the range of less than 60 ml/min/1.73 m2 but not declared ESRD (3) Patients who are not yet recruited for other pharmacological or medical device clinical trials. Exclusion Criteria: (1) Age <18 years (2) Patient on hemodialysis or peritoneal dialysis (3) Simultaneous participation in another interventional study (4) Percutaneous coiling/embolization procedures of the kidney (5) Impossibility to perform RIPC, caused by pathology in both arms (e.g. dystrophy, recent trauma, chronic wounds) (6) No written informed consent (7) Urgent angiography in STEMI (8) Cardiogenic shock requiring catecholamine infusion (9) Systolic blood pressure <80 mmHg (10) Intra-aortic balloon counter-pulsation (11) Contrast medium injection within the previous 30 days (12) Expected impossibility to obtain follow-up data at 6-week follow-up (13) Patients with Raynaud's disease
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Salman Salehin, MD
Phone
+12818189321
Email
sasalehi@utmb.edu
First Name & Middle Initial & Last Name or Official Title & Degree
Khaled Chatila, MD
Phone
+14436005821
Email
kfchatil@utmb.edu
Facility Information:
Facility Name
University of Texas- Medical Branch (UTMB)
City
Galveston
State/Province
Texas
ZIP/Postal Code
77555
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Salman Salehin, MD
Phone
281-818-9321
Email
sasalehi@utmb.edu
First Name & Middle Initial & Last Name & Degree
Wissam I Khalife, MD
Phone
+17137022817
Email
wikhalif@utmb.edu

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
22735306
Citation
Er F, Nia AM, Dopp H, Hellmich M, Dahlem KM, Caglayan E, Kubacki T, Benzing T, Erdmann E, Burst V, Gassanov N. Ischemic preconditioning for prevention of contrast medium-induced nephropathy: randomized pilot RenPro Trial (Renal Protection Trial). Circulation. 2012 Jul 17;126(3):296-303. doi: 10.1161/CIRCULATIONAHA.112.096370. Epub 2012 Jun 26.
Results Reference
background
PubMed Identifier
19556381
Citation
Solomon RJ, Mehran R, Natarajan MK, Doucet S, Katholi RE, Staniloae CS, Sharma SK, Labinaz M, Gelormini JL, Barrett BJ. Contrast-induced nephropathy and long-term adverse events: cause and effect? Clin J Am Soc Nephrol. 2009 Jul;4(7):1162-9. doi: 10.2215/CJN.00550109. Epub 2009 Jun 25.
Results Reference
background
PubMed Identifier
12010907
Citation
Rihal CS, Textor SC, Grill DE, Berger PB, Ting HH, Best PJ, Singh M, Bell MR, Barsness GW, Mathew V, Garratt KN, Holmes DR Jr. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation. 2002 May 14;105(19):2259-64. doi: 10.1161/01.cir.0000016043.87291.33.
Results Reference
background
PubMed Identifier
16177006
Citation
Chertow GM, Burdick E, Honour M, Bonventre JV, Bates DW. Acute kidney injury, mortality, length of stay, and costs in hospitalized patients. J Am Soc Nephrol. 2005 Nov;16(11):3365-70. doi: 10.1681/ASN.2004090740. Epub 2005 Sep 21.
Results Reference
background
PubMed Identifier
15153571
Citation
Lassnigg A, Schmidlin D, Mouhieddine M, Bachmann LM, Druml W, Bauer P, Hiesmayr M. Minimal changes of serum creatinine predict prognosis in patients after cardiothoracic surgery: a prospective cohort study. J Am Soc Nephrol. 2004 Jun;15(6):1597-605. doi: 10.1097/01.asn.0000130340.93930.dd.
Results Reference
background
PubMed Identifier
15464318
Citation
Mehran R, Aymong ED, Nikolsky E, Lasic Z, Iakovou I, Fahy M, Mintz GS, Lansky AJ, Moses JW, Stone GW, Leon MB, Dangas G. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol. 2004 Oct 6;44(7):1393-9. doi: 10.1016/j.jacc.2004.06.068.
Results Reference
background
PubMed Identifier
23176376
Citation
Piskinpasa S, Altun B, Akoglu H, Yildirim T, Agbaht K, Yilmaz R, Peynircioglu B, Cil B, Aytemir K, Turgan C. An uninvestigated risk factor for contrast-induced nephropathy in chronic kidney disease: proteinuria. Ren Fail. 2013;35(1):62-5. doi: 10.3109/0886022X.2012.741646. Epub 2012 Nov 23.
Results Reference
background
PubMed Identifier
18438718
Citation
Rosenstock JL, Bruno R, Kim JK, Lubarsky L, Schaller R, Panagopoulos G, DeVita MV, Michelis MF. The effect of withdrawal of ACE inhibitors or angiotensin receptor blockers prior to coronary angiography on the incidence of contrast-induced nephropathy. Int Urol Nephrol. 2008;40(3):749-55. doi: 10.1007/s11255-008-9368-1. Epub 2008 Apr 26.
Results Reference
background
PubMed Identifier
29130810
Citation
Weisbord SD, Gallagher M, Jneid H, Garcia S, Cass A, Thwin SS, Conner TA, Chertow GM, Bhatt DL, Shunk K, Parikh CR, McFalls EO, Brophy M, Ferguson R, Wu H, Androsenko M, Myles J, Kaufman J, Palevsky PM; PRESERVE Trial Group. Outcomes after Angiography with Sodium Bicarbonate and Acetylcysteine. N Engl J Med. 2018 Feb 15;378(7):603-614. doi: 10.1056/NEJMoa1710933. Epub 2017 Nov 12.
Results Reference
background
PubMed Identifier
25759106
Citation
Jurado-Roman A, Hernandez-Hernandez F, Garcia-Tejada J, Granda-Nistal C, Molina J, Velazquez M, Albarran A, Tascon J. Role of hydration in contrast-induced nephropathy in patients who underwent primary percutaneous coronary intervention. Am J Cardiol. 2015 May 1;115(9):1174-8. doi: 10.1016/j.amjcard.2015.02.004. Epub 2015 Feb 12.
Results Reference
background
PubMed Identifier
25318787
Citation
Luo Y, Wang X, Ye Z, Lai Y, Yao Y, Li J, Liu X. Remedial hydration reduces the incidence of contrast-induced nephropathy and short-term adverse events in patients with ST-segment elevation myocardial infarction: a single-center, randomized trial. Intern Med. 2014;53(20):2265-72. doi: 10.2169/internalmedicine.53.1853. Epub 2014 Oct 15.
Results Reference
background
PubMed Identifier
24856027
Citation
Brar SS, Aharonian V, Mansukhani P, Moore N, Shen AY, Jorgensen M, Dua A, Short L, Kane K. Haemodynamic-guided fluid administration for the prevention of contrast-induced acute kidney injury: the POSEIDON randomised controlled trial. Lancet. 2014 May 24;383(9931):1814-23. doi: 10.1016/S0140-6736(14)60689-9.
Results Reference
background
PubMed Identifier
17707752
Citation
Hausenloy DJ, Mwamure PK, Venugopal V, Harris J, Barnard M, Grundy E, Ashley E, Vichare S, Di Salvo C, Kolvekar S, Hayward M, Keogh B, MacAllister RJ, Yellon DM. Effect of remote ischaemic preconditioning on myocardial injury in patients undergoing coronary artery bypass graft surgery: a randomised controlled trial. Lancet. 2007 Aug 18;370(9587):575-9. doi: 10.1016/S0140-6736(07)61296-3.
Results Reference
background
PubMed Identifier
19995115
Citation
Walsh SR, Boyle JR, Tang TY, Sadat U, Cooper DG, Lapsley M, Norden AG, Varty K, Hayes PD, Gaunt ME. Remote ischemic preconditioning for renal and cardiac protection during endovascular aneurysm repair: a randomized controlled trial. J Endovasc Ther. 2009 Dec;16(6):680-9. doi: 10.1583/09-2817.1.
Results Reference
background
PubMed Identifier
17846333
Citation
Ali ZA, Callaghan CJ, Lim E, Ali AA, Nouraei SA, Akthar AM, Boyle JR, Varty K, Kharbanda RK, Dutka DP, Gaunt ME. Remote ischemic preconditioning reduces myocardial and renal injury after elective abdominal aortic aneurysm repair: a randomized controlled trial. Circulation. 2007 Sep 11;116(11 Suppl):I98-105. doi: 10.1161/circulationaha.106.679167.
Results Reference
background
PubMed Identifier
28610773
Citation
Atanda AC, Olafiranye O. Contrast-induced acute kidney injury in interventional cardiology: Emerging evidence and unifying mechanisms of protection by remote ischemic conditioning. Cardiovasc Revasc Med. 2017 Oct-Nov;18(7):549-553. doi: 10.1016/j.carrev.2017.06.001. Epub 2017 Jun 6.
Results Reference
background
PubMed Identifier
25362220
Citation
Savaj S, Savoj J, Jebraili I, Sezavar SH. Remote ischemic preconditioning for prevention of contrast-induced acute kidney injury in diabetic patients. Iran J Kidney Dis. 2014 Nov;8(6):457-60.
Results Reference
background
PubMed Identifier
27814282
Citation
Zagidullin NS, Dunayeva AR, Plechev VV, Gilmanov AZ, Zagidullin SZ, Er F, Pavlov VN. Nephroprotective effects of remote ischemic preconditioning in coronary angiography. Clin Hemorheol Microcirc. 2017;65(3):299-307. doi: 10.3233/CH-16184.
Results Reference
background
PubMed Identifier
32861377
Citation
Bafna AA, Shah HC. Remote ischemic preconditioning for prevention of contrast-induced nephropathy - A randomized control trial. Indian Heart J. 2020 Jul-Aug;72(4):244-247. doi: 10.1016/j.ihj.2020.04.010. Epub 2020 May 26.
Results Reference
background
PubMed Identifier
23867300
Citation
Mayor F, Bilgin-Freiert A, Connolly M, Katsnelson M, Dusick JR, Vespa P, Koch S, Gonzalez NR. Effects of remote ischemic preconditioning on the coagulation profile of patients with aneurysmal subarachnoid hemorrhage: a case-control study. Neurosurgery. 2013 Nov;73(5):808-15; discussion 815. doi: 10.1227/NEU.0000000000000098.
Results Reference
background

Learn more about this trial

Effectiveness of Remote Ischemic Preconditioning for Prevention of Contrast Induced Acute Kidney Injury in Patients Undergoing Coronary Angiograms.

We'll reach out to this number within 24 hrs